TG Therapeutics (TGTX, Financial) is making waves in the biotech sector as the fastest-growing company in North America, earning the #1 position on Deloitte's Technology Fast 500 list. The recognition underscores the meteoric rise of BRIUMVI®, its breakthrough treatment for relapsing multiple sclerosis, approved in late 2022. CEO Michael S. Weiss lauded the team's efforts and emphasized the company's commitment to advancing treatment options for multiple sclerosis patients, a sentiment echoed by its 230% year-over-year growth in Q3 2024 revenue.
Fueled by robust market uptake, TG Therapeutics reported $83.3 million in Q3 2024 U.S. BRIUMVI revenue—a 15% increase from the previous quarter—and raised its full-year revenue guidance to $300–305 million. With over 92% of patients showing no disability progression after five years, BRIUMVI continues to redefine therapeutic benchmarks. The company's innovative pipeline, including a subcutaneous version of BRIUMVI and novel CAR-T cell therapies, signals its intent to dominate the autoimmune treatment landscape.
Investors are taking notice as TG Therapeutics combines clinical excellence with operational prowess, ensuring sustained momentum into 2025. With a robust cash position of $341 million, strategic partnerships like FUJIFILM Diosynth Biotechnologies, and ongoing developments in autoimmune therapies, TG Therapeutics is not just meeting expectations—it's reshaping them.
